WRF
ALLO icon

Waddell & Reed Financial’s Allogene Therapeutics ALLO Stock Holding History

Waddell & Reed Financial’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-354,820
Closed -$10.3M – 480
2019
Q1 		$10.3M Sell
354,820
-661,180
-65% -$19.2M 0.03% 421
2018
Q4 		$27.4M Buy
+1,016,000
New +$27M 0.08% 284

Other funds holding ALLO

TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
VM
VV Manager Boston, Massachusetts $114M AUM 59.16% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Waddell & Reed Financial's ALLO Position: Q2 2019 in Review

Waddell & Reed Financial sold out of Allogene Therapeutics (ALLO) in Q2 2019, closing a stake of 354,820 shares — an estimated $10.3M sold.

Waddell & Reed Financial first reported a position in ALLO in Q4 2018 and held it in 2 quarters. The position peaked at $27.4M in Q4 2018. 94 funds tracked by Wall St. Rank hold ALLO as of Q2 2019.

  • Waddell & Reed Financial reported no remaining Allogene Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Waddell & Reed Financial sold 354,820 Allogene Therapeutics shares in Q2 2019, an estimated $10.3M.
  • Waddell & Reed Financial first reported a position in Allogene Therapeutics in Q4 2018 and held it in 2 quarters.
  • Waddell & Reed Financial's Allogene Therapeutics position peaked at $27.4M in Q4 2018.
  • 94 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2019.

Based on Waddell & Reed Financial's 13F filing for Q2 2019, filed 14 Aug 2019.